Garth L Kong (Garth Kong)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 5

Top Topics

Sensitive Detection

Acute Myeloid Leukemia

Gold Nanoparticles

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

Molecular cancer research : MCR

This page only lists publications with an associated author ORCID identifier.

Publications

Julia Somers, Madeleine Fenner, Garth L Kong, Dharani Thirumalaisamy, William M Yashar, Kisan Thapa, Meric Kinali, Olga Nikolova, Ozgun Babur, Emek Demir
A framework for considering prior information in network-based approaches to omics data analysis. Proteomics 23 (21-22) (2023)
William M Yashar, Brittany M Curtiss, Daniel J Coleman, Jake VanCampen, Garth L Kong, Jommel Macaraeg, Joseph Estabrook, Emek Demir, Nicola Long, Daniel Bottomly, Shannon K McWeeney, Jeffrey W Tyner, Brian J Druker, Julia E Maxson, Theodore P Braun
Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia. Molecular cancer research : MCR (2023)
Sarah A Carratt, Garth L Kong, Cody Coblentz, Zachary Schonrock, Lauren Maloney, Benjamin R Weeder, William M Yashar, Rowan Callahan, Hunter Z Blaylock, Colin Coleman, Dan Coleman, Theodore P Braun, Julia E Maxson
RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia development. Leukemia (2023)
Sarah A Carratt, Garth L Kong, Brittany M Curtiss, Zachary Schonrock, Lauren Maloney, Breanna N Maniaci, Hunter Z Blaylock, Adrian Baris, Brian J Druker, Theodore P Braun, Julia E Maxson
Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms. Blood 140 (6) (2022)
Brittany M Curtiss, Jake VanCampen, Jommel Macaraeg, Garth L Kong, Akram Taherinasab, Mitsuhiro Tsuchiya, William M Yashar, Yiu H Tsang, Wesley Horton, Daniel J Coleman, Joseph Estabrook, Theresa A Lusardi, Gordon B Mills, Brian J Druker, Julia E Maxson, Theodore P Braun
PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia. Leukemia 36 (7) (2022)